section name header

Pronunciation

a-ta-ZAN-a-veer

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: protease inhibitors

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Rapidly absorbed ( by food).

Distribution: Enters CSF and semen.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A isoenzyme; 13% excreted unchanged in urine.

Half-life: 7 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POrapid2.5 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

When used in combination with other antiretrovirals

CV: PR interval prolongation, heart block.

Derm: DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, rash, STEVENS-JOHNSON SYNDROME.

Endo: Graves' disease, hyperglycemia.

GI: nausea, liver enzymes, abdominal pain, autoimmune hepatitis, cholelithiasis, diarrhea, HEPATOTOXICITY, hyperbilirubinemia, jaundice, vomiting.

GU: interstitial nephritis, nephrolithiasis.

Metab: fat redistribution.

MS: myalgia, polymyositis.

Neuro: depression, dizziness, Guillain-Barré syndrome, headache, insomnia.
Misc: ANGIOEDEMA, fever, immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Route/Dosage

Renal Impairment

Hepatic Impairment

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Reyataz